Pediatric Hematology/Oncology and ImmunopathologyPediatric Hematology/Oncology and ImmunopathologyВопросы гематологии/онкологии и иммунопатологии в педиатрии1726-17082414-9314Fund Doctors, Innovations, Science for Children73110.24287/1726-1708-2023-22-2-152-158SCHOOL ON TRANSPLANTATION AND CELLUL AR THERAPYШКОЛА ПО ТРАНСПЛАНТАЦИИ И КЛЕТОЧНОЙ ТЕРАПИИAcute graft-versus-host disease following allogeneic hematopoietic stem cell transplantationОстрая реакция «трансплантат против хозяина» после аллогенной трансплантации гемопоэтических стволовых клетокhttps://orcid.org/0000-0002-0566-053XSkvortsovaYu. V.СкворцоваЮ. В.
Russian Federation

Yulia V. Skvortsova, Dr. Med. Sci., hematologist, Deputy Head of Department

Hematopoietic Stem Cell Transplantation Department № 2

117997

1 Samory Mashela St.

Moscow

Юлия Валериевна Скворцова, д-р мед. наук, врач-гематолог, заместитель заведующего отделением

отделение трансплантации гемопоэтических стволовых клеток № 2

117997

ул. Саморы Машела, 1

Москва

yuscvo@mail.ruhttps://orcid.org/0000-0002-0016-6698MaschanA. A.МасчанА. А.
Russian Federation

Moscow

Москва

Dmitry Rogachev National Medical Research Center of Pediatric Hematology, Oncology and Immunology of Ministry of Healthcare of the Russian FederationФГБУ «Национальный медицинский исследовательский центр детской гематологии, онкологии и иммунологии им. Дмитрия Рогачева» Минздрава России080720232221521580703202324052023Copyright ©; 2025, «D. Rogachev NMRCPHOI»Copyright ©; 2025, ФГБУ «НМИЦ ДГОИ им. Дмитрия Рогачева» Минздрава России2025«D. Rogachev NMRCPHOI»ФГБУ «НМИЦ ДГОИ им. Дмитрия Рогачева» Минздрава Россииhttps://creativecommons.org/licenses/by/4.0https://hemoncim.com/jour/article/view/731

   Acute graft-versus-host disease (GVHD) remains a major complication of allogeneic hematopoietic stem cell transplantation determining the prognosis of hematopoietic stem cell recipients because of the impairment of multiple organs and systems and subsequent secondary immunodeficiency caused by combination immunosuppressive therapy. Current strategies are focused on the prevention of this life-threatening complication and on the timely start of treatment with appropriate selection of medications based on the knowledge of acute GVHD pathogenesis and grading as well as of risk factors for its development / progression in different patients. Here we provide a brief overview of acute GVHD and the existing approaches to its prevention and treatment.

   Острая реакция «трансплантат против хозяина» остается ведущим осложнением аллогенной трансплантации гемопоэтических стволовых клеток, определяющим прогноз реципиентов гемопоэтических стволовых клеток, в связи с поражением множества органов и систем с формированием глубокого вторичного иммунодефицита на фоне комбинированной, иммуносупрессивной терапии. Современные подходы направлены на профилактику данного жизнеугрожающего осложнения и своевременное начало терапии с подбором эффективных препаратов, основанном на знаниях о патогенезе и стадировании острой реакции «трансплантат против хозяина», факторах риска ее развития и / или прогрессирования у пациентов. Мы представляем краткий обзор данного осложнения и способов его предотвращения и лечения.

acute graft-versus-host diseaseallogeneic hematopoietic stem cell transplantationострая реакция «трансплантат против хозяина»аллогенная трансплантация гемопоэтических стволовых клетокNot specifiedНе указано1. Ferrara J. L., Deeg H. J. Graft-versus-host disease. New Engl J Med 1991; 324 (10): 667–74.Ferrara J. L., Deeg H. J. Graft-versus-host disease. New Engl J Med 1991; 324 (10): 667–74.2. Zeiser R. Advances in understanding the pathogenesis of graft-versus-host disease. Br J Hematol 2019; 187: 563–72.Zeiser R. Advances in understanding the pathogenesis of graft-versus-host disease. Br J Hematol 2019; 187: 563–72.3. Billingham R. E. The biology of graft-versus-host reactions. Harvey Lect 1966; 62: 21–78.Billingham R. E. The biology of graft-versus-host reactions. Harvey Lect 1966; 62: 21–78.4. Coghill J. M., Sarantopoulos S., Moran T. P., Murphy W. J., Blazar B. R., Serody J. S. Effector CD4+ T cells, the cytokines they generate, and GVHD: something old and something new. Blood 2011; 117 (12): 3268–76.Coghill J. M., Sarantopoulos S., Moran T. P., Murphy W. J., Blazar B. R., Serody J. S. Effector CD4+ T cells, the cytokines they generate, and GVHD: something old and something new. Blood 2011; 117 (12): 3268–76.5. Zeiser R., Blazar B. R. Acute graft-versus-host disease Biology, Prevention and Therapy. N Engl J Med 2017; 377 (22): 2167–79.Zeiser R., Blazar B. R. Acute graft-versus-host disease Biology, Prevention and Therapy. N Engl J Med 2017; 377 (22): 2167–79.6. Flowers M. E., Inamoto Y., Carpenter P. A., Lee S. J., Kiem H. P., Petersdorf E. W., et al. Comparative analysis of risk factors for acute graft-versus-host disease and for chronic graft-versus-host disease according to National Institutes of Health consensus criteria. Blood 2011; 117 (11): 3214–9.Flowers M. E., Inamoto Y., Carpenter P. A., Lee S. J., Kiem H. P., Petersdorf E. W., et al. Comparative analysis of risk factors for acute graft-versus-host disease and for chronic graft-versus-host disease according to National Institutes of Health consensus criteria. Blood 2011; 117 (11): 3214–9.7. Jagasia M. H., Grinix H. T., Arora M., Williams R. M., Wolff D., Cowen E. W., et al. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group report. Biol Blood Marrow Transplant 2015; 21 (3): 389–401.Jagasia M. H., Grinix H. T., Arora M., Williams R. M., Wolff D., Cowen E. W., et al. National Institutes of Health Consensus Development Project on Criteria for Clinical Trials in Chronic Graft-versus-Host Disease: I. The 2014 Diagnosis and Staging Working Group report. Biol Blood Marrow Transplant 2015; 21 (3): 389–401.8. Couriel D., Caldera H., Champlin R. Acute graft-versus-host disease: pathophysiology, clinical manifestations, and management. Cancer 2004; 101 (9): 1936–46.Couriel D., Caldera H., Champlin R. Acute graft-versus-host disease: pathophysiology, clinical manifestations, and management. Cancer 2004; 101 (9): 1936–46.9. Robert Z., Takanori T. Nonclassical manifestations of acute GVHD. Вlood 2021; 138 (22): 2165–72.Robert Z., Takanori T. Nonclassical manifestations of acute GVHD. Вlood 2021; 138 (22): 2165–72.10. Glucksberg H., Storb R., Fefer A., Buckner C. D, Neiman P. E., Clift R. A., et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation 1974; 18 (4): 295–304.Glucksberg H., Storb R., Fefer A., Buckner C. D, Neiman P. E., Clift R. A., et al. Clinical manifestations of graft-versus-host disease in human recipients of marrow from HL-A-matched sibling donors. Transplantation 1974; 18 (4): 295–304.11. Przepiorka D., Weisdorf D., Martin P., Klingemann H. G., Beatty P., Hows J., Thomas E. D. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant 1995; 15 (6): 825–8.Przepiorka D., Weisdorf D., Martin P., Klingemann H. G., Beatty P., Hows J., Thomas E. D. 1994 Consensus Conference on Acute GVHD Grading. Bone Marrow Transplant 1995; 15 (6): 825–8.12. Apperly J., Masszi T. Graft-versus-host disease. Chapter 13. In: Apperley J., Carreras E., Gluckman E., Masszi T. (еds.). The 2012 revised edition of the EBMT-ESH Handbook on Haematopoietic Stem Cell Transplantation. 6th Edition; 2012. Pр. 217–33.Apperly J., Masszi T. Graft-versus-host disease. Chapter 13. In: Apperley J., Carreras E., Gluckman E., Masszi T. (еds.). The 2012 revised edition of the EBMT-ESH Handbook on Haematopoietic Stem Cell Transplantation. 6th Edition; 2012. Pр. 217–33.13. Bacigalupo A., Lamparelli T., Barisione G., Bruzzi P., Guidi S., Alessandrino P. E., et al. Thymoglobulin prevents chronic graft-versus-host disease, chronic lung dysfunction, and late transplant-related mortality: long-term follow-up of a randomized trial in patients undergoing unrelated donor transplantation. Biol Blood Marrow Transplant 2006; 12 (5): 560–5.Bacigalupo A., Lamparelli T., Barisione G., Bruzzi P., Guidi S., Alessandrino P. E., et al. Thymoglobulin prevents chronic graft-versus-host disease, chronic lung dysfunction, and late transplant-related mortality: long-term follow-up of a randomized trial in patients undergoing unrelated donor transplantation. Biol Blood Marrow Transplant 2006; 12 (5): 560–5.14. Масчан М. А. Деплеция альфа / бета-Т-лимфоцитов – надежная платформа для развития трансплантации гемопоэтических стволовых клеток от гаплоидентичных доноров / М. А. Масчан // Российский журнал детской гематологии и онкологии. – 2015. – 2 (3): 34–8.Масчан М. А. Деплеция альфа / бета-Т-лимфоцитов – надежная платформа для развития трансплантации гемопоэтических стволовых клеток от гаплоидентичных доноров / М. А. Масчан // Российский журнал детской гематологии и онкологии. – 2015. – 2 (3): 34–8.15. Nunes N. S., Kanakry C. G. Mechanisms of Graft-versus-Host Disease Prevention by Post-transplantation Cyclophosphamide: An Evolving Understanding. Front Immunol 2019; 10: 2668.Nunes N. S., Kanakry C. G. Mechanisms of Graft-versus-Host Disease Prevention by Post-transplantation Cyclophosphamide: An Evolving Understanding. Front Immunol 2019; 10: 2668.16. Масчан А. А. Протокол ТГСК. Стандартные операционные процедуры (ФНКЦ ДГОИ им. Дмитрия Рогачева) / А. А. Масчан [и др.] – 2015. – С. 84, 95–8.Масчан А. А. Протокол ТГСК. Стандартные операционные процедуры (ФНКЦ ДГОИ им. Дмитрия Рогачева) / А. А. Масчан [и др.] – 2015. – С. 84, 95–8.17. Choe H., Ferrara J. New therapeutic targets and biomarkers for acute graft-versus host disease (GVHD). Expert Opin Ther Targets 2021; 25 (9): 761–71.Choe H., Ferrara J. New therapeutic targets and biomarkers for acute graft-versus host disease (GVHD). Expert Opin Ther Targets 2021; 25 (9): 761–71.18. Vogelsang G. B, Lee L., Bensen-Kennedy D. M. Pathogenesis and treatment of graft-versus-host disease after bone marrow transplant. Ann Rev Med 2003; 54: 29–52.Vogelsang G. B, Lee L., Bensen-Kennedy D. M. Pathogenesis and treatment of graft-versus-host disease after bone marrow transplant. Ann Rev Med 2003; 54: 29–52.19. Martin P. J., Schoch G., Fisher L. A retrospective analysis of therapy for acute graft-versus-host disease: initial treatment. Blood 1990; 76 (8): 1464–72.Martin P. J., Schoch G., Fisher L. A retrospective analysis of therapy for acute graft-versus-host disease: initial treatment. Blood 1990; 76 (8): 1464–72.20. Greinix H. T., Worel N., Just U., Knobler R. Extracorporeal photopheresis in acute and chronic graft-versus-host disease. Transfus Apher Sci 2014; 50 (3): 349–57.Greinix H. T., Worel N., Just U., Knobler R. Extracorporeal photopheresis in acute and chronic graft-versus-host disease. Transfus Apher Sci 2014; 50 (3): 349–57.21. Penack O., Marchetti M., Ruutu T., Aljurf M., Bacigalupo A., Bonifazi F., et al. Prophylaxis and management of graft versus host disease after stem-cell transplantation for haematological malignancies: updated consensus recommendations of the European Society for Blood and Marrow Transplantation. Lancet Haematol 2020; (2): e157–67.Penack O., Marchetti M., Ruutu T., Aljurf M., Bacigalupo A., Bonifazi F., et al. Prophylaxis and management of graft versus host disease after stem-cell transplantation for haematological malignancies: updated consensus recommendations of the European Society for Blood and Marrow Transplantation. Lancet Haematol 2020; (2): e157–67.